Skip to main content

Supernus Pharmaceuticals

Supernus Pharmaceuticals Inc is an American biopharmaceutical company focused on central nervous system therapies for neurological and psychiatric disorders. The company develops and commercializes prescription medicines including Qelbree for ADHD, Oxtellar XR and Trokendi XR for epilepsy, and Gocovri and APOKYN for Parkinson's disease. Main revenue drivers consist of commercial drug sales of proprietary CNS prescription pharmaceuticals through pharmaceutical wholesalers and specialty pharmacies. Supernus Pharmaceuticals serves psychiatrists, neurologists, movement disorder specialists, and patients across the United States. The company holds an established market position in central nervous system therapeutics and Parkinson's disease management. Headquartered in Rockville, Maryland, Supernus Pharmaceuticals Inc is listed on the Nasdaq Stock Market.

4 of the funds FundTelligence covers report a position in Supernus Pharmaceuticals.

Legal name
Supernus Pharmaceuticals Inc
Sector
Health Care
Country
United States
Funds holding it
4
Exposure themes
ADHD, Mental Health, Neuropsychiatry

Funds holding Supernus Pharmaceuticals

Loading...